Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

First Specific Drug Therapy Approved for the Treatment of PKU

NOVATO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU). Shipments to the distribution channel will commence tomorrow, and BioMarin will begin promotion of Kuvan immediately.

"The approval of Kuvan represents an important milestone for PKU patients and their families and also for BioMarin. We are extremely pleased to bring this promising treatment option to market in just a little over three years since the IND filing, and we are now ready for an immediate launch," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We would like to thank all the patients, their families and physicians, our corporate partners, the FDA, and BioMarin employees for their hard work and dedication in making Kuvan a reality."

"In clinical trials, Kuvan has been shown to help control blood Phe levels in PKU patients, and I am thrilled that this new therapy is now commercially available to the PKU community," stated Dr. Barbara Burton, Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Director, PKU Clinic at Children's Memorial Hospital; and Clinical Investigator in the Kuvan Phase 2 and Phase 3 trials. "With Kuvan now approved, physicians and patients have, for the first time, a drug therapy option to manage the disease."

Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) responsive PKU and is to be used in conjunction with a Phe-restricted diet. To determine if there is a response to Kuvan, the recommended starting dose of Kuvan is 10 mg/kg/day taken once daily for up to a month. If there
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 2007 /PRNewswire/ -- DNA Therapeutics,S.A. an emerging pharmaceutical ... elucidation of a new mechanism,of action and the ... molecule Dbait. It will be,presented at the forecoming ... abstract is now available online.,The presentation itself will ...
... Potent Synergy, Activity and Patient Tolerance Support ... Spain, April 12, 2007 /PRNewswire/ -- Intarcia,Therapeutics, ... final results from a Phase 2 study ... treatment-naive patients,with genotype 1 chronic hepatitis C. ...
Cached Medicine Technology:DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 2DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4
(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) -- ... But it was a physical challenge in her childhood ... sport. "I was an 11-year-old girl with my ... diagnosed by my orthopedic surgeon," said Lewis, who has ... and the American Academy of Orthopaedic Surgeons so she ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... found that the United States, which has the most expensive ... rich countries for quality, access and efficiency of healthcare. ... performance, to other countries and differs most notably in the ... to the studies. ,Says Commonwealth Fund president ...
... experts in India are questioning the efficacy of the ... the country. The increasing number of TB cases ... with how the DOTS strategy has been implemented, according ... has implemented various TB control programs that are used ...
... on Tuesday said that Thailand will not issue compulsory ... if pharmaceutical companies offer prices lower than those charged ... came one day after Abbott Laboratories and Thailand failed ... antiretroviral drugs Aluvia and Kaletra. ,The Thai ...
... in doctors reflects the reality in the NHS. It is ... doctors to improve the quality and experience of care for ... service. ,In virtually all of the questions patients ... answered that doctors are providing high standards of care. ...
... most common but contentious accommodation requests made by students ... entrance and licensing exams. According to a new study ... time respond to exams similarly to average students under ... there is no real evidence to suggest that the ...
... East Anglia in Norwich and Kings College in London, has ... used to find out not only the kind of drugs ... diseases. ,Lead researcher, David A. Russell, and his ... about the lifestyle of the person whose fingerprints have been ...
Cached Medicine News:Health News:Americans Get Least Value For Money In Healthcare 2Health News:Thailand Will Not Issue Compulsory Licenses for Patented Drugs 2Health News:Now Fingerprints can Be Used to Detect Drugs and Diseases Instead of Blood Samples 2
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Marco Radiusgauges are available with either a ... in either monocular or binocular form. All ... one, measuring both the curvature and thickness ... The accuracy of both measurements is increased ...
... or for those seeking high quality ... is an economical, full-function instrument-delivery system. ... body offer rugged, maintenance-free service. And ... two arms provided as standard equipment--adjusts ...
... Marco could offer you a choice of two ... Chart Projector uses a halogen bulb for longer ... use. The Marco Chart Projector offers a lower ... includes a thermistor for extended bulb life. And ...
Medicine Products: